A trial looking at surgery with or without chemotherapy for people with cancer of the stomach or food pipe (oesophagus or gullet) (MAGIC ST02)

Cancer type:

Oesophageal cancer
Stomach cancer




Phase 3

This trial compared surgery and chemotherapy with surgery alone, for people with stomach cancer, cancer of the lower part of the food pipe (oesophageal cancer), or where the oesophagus meets the stomach (the gastro-oesophageal junction).

Doctors may be able to treat cancer of the stomach cancer, gastro-oesophageal junction or oesophagus cancer with surgery. But sometimes the cancer can still come back afterwards (recur). So they are always looking for new ways to improve treatment. In this trial they wanted to see if having ECF chemotherapy before and after surgery could help stop the cancer from coming back. ECF is epirubicin, cisplatin and 5 fluorouracil (5FU).

The aims of the trial were to find out

  • If having surgery and chemotherapy is better than surgery alone for stomach, gastro-oesophageal or oesophageal cancer
  • More about the side effects of ECF

Summary of results

The research team found that ECF chemotherapy together with surgery is a useful treatment combination for people with cancer of the oesophagus, gastro-oesophageal junction or stomach.

The trial recruited 503 people

  • Half had surgery alone
  • Half had chemotherapy before and after their surgery

The researchers analysed and published the results in 2006. They looked at whose cancer had come back after surgery. They found that the cancer came back more often in people who had surgery alone compared to the people who had surgery and chemotherapy.

The researchers also found that the cancer removed from the people who had ECF chemotherapy before surgery was smaller and less advanced than in people who did not have chemotherapy.

The side effects of ECF did not stop people from going on to have their surgery. Only a very small number of people had any severe side effects. And this was mainly a drop in white blood cells (neutropenia)

We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) and published in a medical journal. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr David Cunningham

Supported by

Medical Research Council (MRC)
NIHR Clinical Research Network: Cancer

If you have questions about the trial please contact our cancer information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 152

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Around 1 in 5 people take part in clinical trials

3 phases of trials

Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think